Cancer cachexia remains a major unmet clinical challenge, contributing to morbidity, reduced quality of life, and mortality across diverse cancer types. Despite its high prevalence—estimated to affect over half of all cancer-related deaths globally—there is currently no standardized treatment or licensed therapy available. The syndrome is characterized by progressive loss of skeletal muscle mass, often accompanied by fat depletion, which cannot be fully reversed by nutritional support alone. This multifactorial condition results from a complex interplay between tumor-derived factors and host responses, particularly involving chronic systemic inflammation. Among the key mediators implicated in this process is interleukin-1 (IL-1), a potent pro-inflammatory cytokine that plays a central role in driving the metabolic and neuroendocrine alterations seen in cachexia.
IL-1 is primarily produced by activated monocytes, macrophages, and neutrophils in response to inflammatory stimuli. In the context of cancer, elevated levels of IL-1 are observed due to persistent tumor-host interactions, leading to upregulation of downstream inflammatory cascades including IL-6 and other mediators. This sustained inflammatory state disrupts normal energy homeostasis, promoting catabolism and suppressing appetite. Preclinical evidence demonstrates that IL-1 directly activates hypothalamic pathways via the hypothalamic-pituitary-adrenal (HPA) axis. Specifically, IL-1 stimulates corticotropin-releasing hormone (CRH) release, triggering adrenocorticotropic hormone (ACTH) and cortisol secretion, both of which contribute to muscle proteolysis and adipose tissue lipolysis. Furthermore, IL-1 modulates central appetite regulation by influencing neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) neurons, ultimately suppressing food intake through activation of melanocortin-4 receptors (MC4-R).
Clinical studies have reinforced the link between IL-1 and cachexia progression. Elevated serum IL-1 levels correlate with weight loss, reduced lean body mass, anorexia, and poor survival outcomes in patients with gastrointestinal, lung, and pancreatic cancers. Notably, genetic polymorphisms such as IL-1β +3954 have been identified as risk factors for developing cachexia, highlighting a potential hereditary component to disease susceptibility. These findings underscore the biological plausibility of targeting IL-1 as a therapeutic strategy.
Recent advances in biologic therapeutics have brought renewed attention to IL-1 inhibition. Canakinumab, a human monoclonal antibody that neutralizes circulating IL-1β, has demonstrated efficacy in reducing cardiovascular events in the CANTOS trial. Intriguingly, a secondary analysis revealed a decreased incidence of lung cancer among patients receiving higher doses of canakinumab, suggesting anti-tumor and potentially anti-cachectic effects. Although current trials focus predominantly on survival endpoints, there is growing interest in evaluating canakinumab’s impact on cachexia-specific outcomes such as muscle mass preservation, appetite improvement, and functional status.ACHE Antibody manufacturer Ongoing CANOPY trials in lung cancer may provide critical insights into this potential application.ATG5 Antibody web
Despite promising mechanistic rationale, targeted IL-1 therapies have not yet been formally tested in dedicated cachexia trials.PMID:34418275 Future research should prioritize patient populations at high risk of cachexia, incorporating sensitive endpoints that capture the full spectrum of clinical manifestations. Given canakinumab’s favorable safety profile and established tolerability in real-world settings, exploratory trials examining its use in combination with standard supportive care could offer a transformative approach to managing cancer cachexia. Ultimately, modulating the IL-1 pathway represents a compelling avenue for addressing both the metabolic dysfunction and systemic inflammation underlying this debilitating syndrome.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
